Kyruus Secures $30 Million Investment from Francisco Partners New Funding Will Accelerate Company’s Ability to Support Healthcare Organizations Caring for Patients During Unprecedented Time Boston, MA and San Francisco, CA – June 10, 2020 – Kyruus, the leader in...
New Research Sheds Light on Intentional Non-adherence in Clinical Trials First-of-its-kind study leverages objective adherence data collected by AiCure to illustrate scope of intentional non-adherence Study findings help inform best practices to lower non-adherence...
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile...
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses Principia to...
Neurana Pharmaceuticals Announces Publication of Driving Study SAN DIEGO, Calif., May 12, 2020 – Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the publication of a driving...
Recent Comments